J0593 HCPCS Level II code: Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is…
J0593 is the HCPCS code for “Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0593Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
Short description: Inj., lanadelumab-flyo, 1 mg
HCPCS · United States
Medicare details
The indicators CMS publishes with J0593 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Oct 1, 2019
Where J0593 sits
- 1J codesDrugs administered other than orally
- 2Active code J0593Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0593 mean?
J0593 is the HCPCS code for “Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0593?
CMS lists J0593’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0593
All J codesJ0586Injection, abobotulinumtoxina, 5 unitsJ0587Injection, rimabotulinumtoxinb, 100 unitsJ0588Injection, incobotulinumtoxin a, 1 unitJ0589Injection, daxibotulinumtoxina-lanm, 1 unitJ0591Injection, deoxycholic acid, 1 mgJ0592Injection, buprenorphine hydrochloride, 0.1 mgJ0594injection, busulfan, 1 mgJ0595Injection, butorphanol tartrate, 1 mgJ0596Injection, c1 esterase inhibitor (recombinant), ruconest, 10 unitsJ0597Injection, c-1 esterase inhibitor (human), berinert, 10 unitsJ0598Injection, c-1 esterase inhibitor (human), cinryze, 10 unitsJ0599Injection, c-1 esterase inhibitor (human), (haegarda), 10 units